Yubo Biotech Confirms Board, Auditor Amid Going Concern Warning
Summary
Yubo International Biotech filed a DEF 14C confirming director elections and auditor ratification, but the filing reinforces the company's critical financial state, including a 'going concern' warning and past highly dilutive insider financing.
Key Events
-
Director Elections Confirmed
Four directors, including the CEO, President, and CFO, were re-elected by majority shareholder consent. The board operates without formal meetings or standing committees, relying on written consents.
-
Auditor Ratification
HCL, PLLC was ratified as the independent auditor for 2025 and 2026, following the resignation of previous auditor HHL LLP in January 2026. HHL's prior report included a 'going concern' explanatory paragraph.
-
Historical Dilutive Insider Financing
The filing discloses a July 2025 transaction where 50.6 million shares were issued to entities controlled by the CEO and President at $0.05 per share to settle $2.53 million in shareholder loans. This amount significantly exceeds the company's current market capitalization.
-
Going Concern Context
The company continues to operate under an explicit 'going concern' warning, as reported in its recent Q1 2026 10-Q, with zero revenue and significant net losses.
Analysis
This DEF 14C filing details the routine election of directors and ratification of the auditor, HCL, PLLC, by majority shareholder consent. However, the context of the company's explicit 'going concern' warning from its recent 10-Q, coupled with the disclosure of a highly dilutive historical share issuance to insiders to settle loans (valued at $2.53 million, exceeding the current market cap), highlights severe financial distress and governance concerns. The board's operation solely by written consent and lack of standing committees further underscore the company's precarious situation.
At the time of this filing, YBGJ was trading at $0.01 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.01 to $1.37. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.